Incruse Ellipta Drug Interactions: What to Avoid and What to Tell Your Doctor

Incruse Ellipta (umeclidinium) works by blocking muscarinic receptors throughout the body. While the medication is targeted at the lungs, some of its effects reach other organ systems — and certain other medications work through the same pathway. When these medications are taken together, the combined anticholinergic effects can become amplified and cause serious adverse reactions. Here's everything you need to know about Incruse Ellipta drug interactions.

The Most Important Interaction: Other Anticholinergic Medications

The prescribing information for Incruse Ellipta includes a specific warning: do not use it with other anticholinergic medications. Anticholinergics block the same muscarinic receptors as umeclidinium. Taking two or more anticholinergics simultaneously creates additive blockade — dramatically increasing the risk of:

• Worsening narrow-angle glaucoma (increased intraocular pressure, eye pain, vision changes)
• Severe urinary retention (inability to urinate)
• Severe constipation
• Confusion and cognitive impairment (particularly in elderly patients)
• Dry mouth, blurred vision, rapid heartbeat

Major Interactions to Avoid: Other Inhaled LAMAs

Never combine Incruse Ellipta with other inhaled long-acting anticholinergics:

• Tiotropium (Spiriva HandiHaler or Respimat): Same LAMA class as umeclidinium. Using both simultaneously provides no clinical benefit and substantially increases anticholinergic toxicity risk. Avoid combination.
• Aclidinium (Tudorza Pressair): Another inhaled LAMA. Combining with Incruse Ellipta is contraindicated for the same reason.
• Glycopyrronium (Seebri Neohaler): Yet another LAMA inhaler. Additive anticholinergic effects — avoid concurrent use.
• Ipratropium (Atrovent HFA): A short-acting anticholinergic bronchodilator. If you're using ipratropium as a rescue medication, you should not also be on Incruse Ellipta. Discuss this with your prescriber.
• Revefenacin (Yupelri): A nebulized LAMA — same class warning applies. Do not use with Incruse Ellipta.

Moderate Interactions: Other Anticholinergic Medications

Even non-inhaled anticholinergics can increase the total anticholinergic burden in your system. Be sure to tell your doctor if you take any of the following:

• Overactive bladder medications: Oxybutynin (Ditropan), tolterodine (Detrol), solifenacin (VESIcare), darifenacin (Enablex), fesoterodine (Toviaz), mirabegron (Myrbetriq). These are anticholinergics that target bladder muscarinic receptors. Combined with Incruse Ellipta, they can significantly worsen urinary retention.
• Parkinson's disease medications: Benztropine (Cogentin), trihexyphenidyl (Artane) are anticholinergics used in Parkinson's disease. Combining with inhaled LAMAs increases overall anticholinergic load.
• Antihistamines with anticholinergic properties: Diphenhydramine (Benadryl), hydroxyzine (Vistaril), chlorpheniramine. Commonly found in OTC allergy, cold, and sleep products. These have significant anticholinergic properties and can add to umeclidinium's effects.
• Tricyclic antidepressants (TCAs): Amitriptyline, nortriptyline, imipramine. TCAs have strong anticholinergic activity. Combined with Incruse Ellipta, risk of urinary retention, constipation, dry mouth, and cognitive effects increases.

Interactions That Reduce Incruse Ellipta's Effectiveness

Some medications can counteract umeclidinium's effects by boosting acetylcholine levels:

• Cholinesterase inhibitors (Alzheimer's drugs): Donepezil (Aricept), rivastigmine (Exelon), galantamine (Razadyne) work by preventing the breakdown of acetylcholine. This increases acetylcholine levels, which partially counteracts umeclidinium's receptor-blocking effects. If you take these medications, Incruse Ellipta may be less effective.

Other Interactions to Know

• Glucagon: Glucagon and anticholinergics both inhibit gastrointestinal motility through different mechanisms. Combined use increases the risk of gastrointestinal adverse reactions including severe constipation and ileus.
• Soft-mist topical anticholinergics: Sofpironium topical (for hyperhidrosis) and glycopyrronium tosylate topical have systemic anticholinergic activity. Combined use with Incruse Ellipta may increase total anticholinergic burden.

What to Tell Your Doctor Before Starting Incruse Ellipta

Always tell your prescriber if you are taking:

• Any other inhaler, especially other COPD inhalers or anticholinergic inhalers
• Bladder medications (for overactive bladder or incontinence)
• Any allergy, sleep, or cold medications (especially OTC diphenhydramine products)
• Antidepressants — especially tricyclics
• Alzheimer's medications or any medication for memory or cognition
• Parkinson's disease medications

Special Caution for Older Adults

Elderly patients are more vulnerable to cumulative anticholinergic effects, including confusion, falls, constipation, and urinary retention. The American Geriatrics Society's Beers Criteria identifies anticholinergics as potentially inappropriate medications in older adults when not clinically necessary. If you're over 65 and taking multiple medications, ask your prescriber to review your full medication list for total anticholinergic burden before starting or continuing Incruse Ellipta. For more on side effects, see our full guide to Incruse Ellipta side effects.